iBio (IBIO) Q1 2027 earnings summary

Executive summary

• Advanced obesity and cardiometabolic programs; IBIO-600 completed dosing in all four planned Phase 1 SAD cohorts, and IBIO-610 generated additional preclinical body-composition data.

• Revenue rose to $1.075 million, while net loss widened to $7.551 million; quarter-end cash and investments totaled $76.7 million.

Financial highlights

• Revenue was $1.075 million versus $100,000 year over year, all from services provided to one collaborative partner.

• R&D expense increased 87% to $6.650 million from $3.550 million; G&A rose to $2.763 million from $2.501 million.

• Operating expenses were $9.413 million versus $6.051 million; operating loss was $8.338 million versus $5.951 million.

• Net loss was $7.551 million versus $5.720 million; loss per share was $0.05 versus $0.11.

• Net cash used in operations was $9.4 million versus $5.7 million.

Outlook and guidance

• IBIO-610 first-in-human studies are targeted for H1 2027; an IND-equivalent filing was targeted by year-end 2026.

• IBIO-600 interim SAD data are anticipated in Q1 2027, with multiple-ascending-dose testing expected to start in Q1 2027.

• An IBIO-800 IND-equivalent filing is anticipated in 1H 2027; discovery candidates are targeted for 2H 2027.

• Cash and debt investments are expected to fund operations into Q4 FY28; potential funding sources include warrant exercises, collaborations, out-licensing and securities offerings, with availability and terms uncertain.